HUT61729A - Process for producing dihydroisoquinoline derivatives and pharmaceutical compositions comprising such compounds - Google Patents

Process for producing dihydroisoquinoline derivatives and pharmaceutical compositions comprising such compounds Download PDF

Info

Publication number
HUT61729A
HUT61729A HU913760A HU376091A HUT61729A HU T61729 A HUT61729 A HU T61729A HU 913760 A HU913760 A HU 913760A HU 376091 A HU376091 A HU 376091A HU T61729 A HUT61729 A HU T61729A
Authority
HU
Hungary
Prior art keywords
formula
physiologically acceptable
compounds
acid addition
compound
Prior art date
Application number
HU913760A
Other languages
English (en)
Hungarian (hu)
Other versions
HU913760D0 (en
Inventor
Reto Naef
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of HU913760D0 publication Critical patent/HU913760D0/hu
Publication of HUT61729A publication Critical patent/HUT61729A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
HU913760A 1990-12-13 1991-12-02 Process for producing dihydroisoquinoline derivatives and pharmaceutical compositions comprising such compounds HUT61729A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909027055A GB9027055D0 (en) 1990-12-13 1990-12-13 Organic compounds

Publications (2)

Publication Number Publication Date
HU913760D0 HU913760D0 (en) 1992-02-28
HUT61729A true HUT61729A (en) 1993-03-01

Family

ID=10686945

Family Applications (1)

Application Number Title Priority Date Filing Date
HU913760A HUT61729A (en) 1990-12-13 1991-12-02 Process for producing dihydroisoquinoline derivatives and pharmaceutical compositions comprising such compounds

Country Status (25)

Country Link
US (1) US5177085A (enExample)
EP (1) EP0490823B1 (enExample)
JP (1) JPH0764820B2 (enExample)
KR (1) KR920012040A (enExample)
AT (1) ATE145201T1 (enExample)
AU (1) AU643575B2 (enExample)
CA (1) CA2057524A1 (enExample)
CZ (1) CZ281669B6 (enExample)
DE (1) DE69123124T2 (enExample)
DK (1) DK0490823T3 (enExample)
ES (1) ES2093694T3 (enExample)
FI (1) FI915844L (enExample)
GB (1) GB9027055D0 (enExample)
GR (1) GR3022034T3 (enExample)
HU (1) HUT61729A (enExample)
IE (1) IE914325A1 (enExample)
IL (1) IL100328A (enExample)
MX (1) MX9102502A (enExample)
MY (1) MY129941A (enExample)
NZ (1) NZ240936A (enExample)
PL (1) PL168329B1 (enExample)
PT (1) PT99775B (enExample)
RU (1) RU2060992C1 (enExample)
TW (1) TW201736B (enExample)
ZA (1) ZA919858B (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9322828D0 (en) * 1993-11-05 1993-12-22 Sandoz Ltd Organic compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
DE69433594T2 (de) * 1993-12-22 2004-08-05 Celltech R&D Ltd., Slough Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412571D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
RU2161967C2 (ru) * 1994-08-18 2001-01-20 Дзе Проктер Энд Гэмбл Компани Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
US5948820A (en) 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
KR100358922B1 (ko) * 1994-08-22 2003-01-24 미쯔비시 웰 파마 가부시키가이샤 벤젠화합물및그의의약으로서의용도
AU4527996A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Trisubstituted thioxanthines
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
US6268373B1 (en) * 1995-06-07 2001-07-31 Euro-Celtique S.A. Trisubstituted thioxanthines
GB9523267D0 (en) * 1995-11-14 1996-01-17 Sandoz Ltd Organic compounds
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
AU2593997A (en) * 1996-03-21 1997-10-10 Trustees Of Columbia University In The City Of New York, The Craf1 (traf-3) isoforms and uses thereof
US6075016A (en) * 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998017636A1 (en) * 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
ID19155A (id) * 1996-12-13 1998-06-18 Tanabe Seiyaku Co Turunan-turunan piridin, pembuatannya dan intermediet untuk pembuatannya
EP0946523A1 (en) 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
WO1998038168A1 (en) * 1997-02-27 1998-09-03 Tanabe Seiyaku Co., Ltd. Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DE69822162T2 (de) * 1997-07-25 2005-01-27 Altana Pharma Ag Neue tetrazolderivate
JP2001518468A (ja) * 1997-09-30 2001-10-16 モレキュラー デザインズ インターナショナル，インコーポレイテッド β３アドレナリン受容体拮抗薬、拮抗薬合成物およびこれらの応用方法
IT1296985B1 (it) * 1997-12-19 1999-08-03 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
IT1302677B1 (it) 1998-10-15 2000-09-29 Zambon Spa Derivati benzazinici inibitori della fosfodiesterasi 4
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
EP1671651B1 (en) 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB9924862D0 (en) * 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP1270577B1 (en) * 2000-03-23 2006-12-06 Takeda Pharmaceutical Company Limited Furoisoquinoline derivatives, process for producing the same and use thereof
AU2954102A (en) 2000-11-14 2002-05-27 Byk Gulden Lomberg Chem Fab (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
WO2002040449A1 (en) * 2000-11-14 2002-05-23 Altana Pharma Ag Dihydroisoquinolines as novel phosphodiesterase inhibitors
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
CA2449118A1 (en) * 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ATE435202T1 (de) 2002-01-11 2009-07-15 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
US7745180B2 (en) 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
RS20050117A (sr) * 2002-08-17 2007-06-04 Altana Pharma Ag., Novi benzonaftiridini
WO2004018431A2 (en) * 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
EP1536798B1 (en) 2002-08-29 2007-02-07 ALTANA Pharma AG 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
CA2495827C (en) 2002-08-29 2012-05-08 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
RU2355686C2 (ru) * 2003-10-16 2009-05-20 Ф.Хоффманн-Ля Рош Аг Ингибиторы глутаминфруктозо-6-фосфатамидотрансферазы
EP1720835B1 (en) 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
RU2332212C2 (ru) 2004-02-24 2008-08-27 Санкио Компани, Лимитед Аминоспирт
PT1723135E (pt) 2004-03-03 2013-08-29 Takeda Gmbh Novas hidroxi-6-heteroarilfenantridinas e sua utilização como inibidores de pde4
RU2281100C1 (ru) * 2005-01-11 2006-08-10 Общество с ограниченной ответственностью "Синтез-2000" Спазмолитическое средство
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
EP3033082B1 (en) 2013-08-16 2021-06-16 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400425A (en) * 1971-09-22 1975-07-16 Rolland Sa A Substituted 3-hydroxymethyl-isoquinolines and derivatives
HU196758B (en) * 1986-05-21 1989-01-30 Gyogyszerkutato Intezet Process for production of 3-hidroxi-methil-quinolines and medical compositions containing them
PH25651A (en) * 1986-05-21 1991-08-21 Duphar Int Res New di, tetrahydroisoquinoline derivatives
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds

Also Published As

Publication number Publication date
NZ240936A (en) 1993-09-27
ES2093694T3 (es) 1997-01-01
RU2060992C1 (ru) 1996-05-27
PT99775B (pt) 1999-05-31
US5177085A (en) 1993-01-05
FI915844A7 (fi) 1992-06-14
IE914325A1 (en) 1992-06-17
TW201736B (enExample) 1993-03-11
KR920012040A (ko) 1992-07-25
PT99775A (pt) 1992-11-30
CA2057524A1 (en) 1992-06-14
MY129941A (en) 2007-05-31
ZA919858B (en) 1993-06-14
MX9102502A (es) 1992-06-01
AU643575B2 (en) 1993-11-18
DK0490823T3 (enExample) 1997-02-17
PL292738A1 (en) 1992-12-14
HU913760D0 (en) 1992-02-28
FI915844A0 (fi) 1991-12-11
EP0490823A1 (en) 1992-06-17
IL100328A (en) 1995-12-08
PL168329B1 (pl) 1996-02-29
CS375791A3 (en) 1992-06-17
GB9027055D0 (en) 1991-02-06
AU8898591A (en) 1992-06-18
IL100328A0 (en) 1992-09-06
EP0490823B1 (en) 1996-11-13
JPH0764820B2 (ja) 1995-07-12
DE69123124T2 (de) 1997-05-15
DE69123124D1 (de) 1996-12-19
CZ281669B6 (cs) 1996-12-11
ATE145201T1 (de) 1996-11-15
FI915844L (fi) 1992-06-14
JPH04275276A (ja) 1992-09-30
GR3022034T3 (en) 1997-03-31

Similar Documents

Publication Publication Date Title
HUT61729A (en) Process for producing dihydroisoquinoline derivatives and pharmaceutical compositions comprising such compounds
RU2144027C1 (ru) Изохинолины, способ их получения и фармацевтическая композиция на их основе
US4980359A (en) Isoquinoline derivatives and their use
FI87356B (fi) Foerfarande foer framstaellning av nya xantinderivat.
JPS62212322A (ja) 医薬組成物および処置法
PT1369419E (pt) Composto de n-fenilarilsulfonamida, fármaco contendo o composto como ingrediente activo, produtos intermédios para a produção do composto e processos para a produção do composto
US4818772A (en) Derivatives of 4-aminoethoxy-5-isopropyl-2-methylbenzenes: methods of synthesis and utilization as medicines
JPS58194859A (ja) １−カルボキシアルカノイルインドリン−２−カルボン酸エステル及びその製造方法、並びに該エステルを含有する医薬
RU2081872C1 (ru) Производные дигидропиридина, смесь их изомеров, индивидуальные изомеры или их физиологически переносимые соли, способы их получения, промежуточные соединения и способ их получения
JPH0692406B2 (ja) キサンチン誘導体、その製造方法およびそれらの医薬としての用途
JPH0676373B2 (ja) グアニジノ安息香酸エステル誘導体
JPS62294614A (ja) ベンゾ〔ｃ〕〔１，６〕ナフチリジン誘導体からなる新規医薬組成物
JP3049284B2 (ja) ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤
JP2928307B2 (ja) ピロリジン誘導体
CN120441641A (zh) 一种靶向ros激活的雷公藤甲素衍生物及其制备方法、以及用途
CS221847B2 (en) Method of making the ethaloamine derivatives
TW202502721A (zh) 一種曲前列環素衍生物、其製備方法及應用
JPWO2001000588A1 (ja) ベンズイミダゾール化合物及びこれを含む医薬
HK40114273A (zh) 一种曲前列环素衍生物、其制备方法及应用
JPWO2002012191A1 (ja) 環状アミン系誘導体及びその用途
JPH0832688B2 (ja) フェノキシ酢酸誘導体及びこれを含有する医薬製剤
RO109541B1 (ro) Derivați de dihidro-izochinolină, procedee de obținere și compoziții farmaceutice
JPS5913509B2 (ja) カルボスチリル誘導体の製造法
JPS6183175A (ja) ベンゾチアゾリン誘導体およびそれを主成分とする循環器官用薬剤
JPH09124608A (ja) シクロプロパン誘導体及びそれを含有する抗ウイルス剤

Legal Events

Date Code Title Description
DGB9 Succession in title of applicant

Owner name: NOVARTIS AG., CH

DFC4 Cancellation of temporary protection due to refusal